Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a/2b Study of Bermekimab vs Placebo and Adalimumab in Moderate to Severe Hidradenitis Suppurativa
2020-002607-19Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bermekimab in hidradenitis suppurativa (HS) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Hidradenitis Suppurativa Clinical Response 50 (HiSCR50). Started Jul 2021; status: completed.
02
Drugs
bermekimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2020-002607-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002607-19.